Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Staphylococcal Sepsis

In brief

Evaluate the safety, PK and efficacy comparing Pagibaximab Injection to placebo in preventing staphylococcal sepsis in very low birth weight infants. 1550 infants will be enrolled prior to 48 hours of life and will be randomized 1:1 to receive active drug or placebo on study days 0, 1, 2, 9, 16, and 23.

Key facts

Study ID
NCT00646399
Run by
Biosynexus Incorporated
People needed
1579
Starts
2009-03-01
Expected to finish
2011-05-01
Last updated by the study team
2011-10-24

Who can join

Age: any, up to 0. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.